Table 3.
Anticancer applications in clinical trials
| Applications | Target site | Study phase | Editing strategy | Clinical trials identification |
|---|---|---|---|---|
| Advanced esophageal cancer | PD-1 | Phase II | PD-1 knockout | NCT03081715 |
| Castration resistant prostate cancer | PD-1 | Phase I | PD-1 knockout | NCT02867345 |
| Muscle-invasive bladder cancer | PD-1 | Phase I | PD-1 knockout | NCT02863913 |
| Metastatic non-small cell lung cancer | PD-1 | Phase I | PD-1 knockout | NCT02793856 |
| EBV associated malignancies | PD-1 | Phase I Phase II |
PD-1 knockout | NCT03044743 |
| Metastatic renal cell carcinoma | PD-1 | Phase I | PD-1 knockout | NCT02867332 |
| Relapsed or refractory leukemia and lymphoma | CD19 and CD20 or CD22 | Phase I Phase II |
Edit CD19 and CD20 or CD22 | NCT03398967 |
| Human papillomavirus-related malignant neoplasm | HPV16-E6/E7 HPV18 E6/E7 |
Phase I | HPV16-E6/E7 or HPV18 E6/E7 knockout |
NCT03057912 |
| CD19 + leukemia and lymphoma | TCR B2M |
Phase I Phase II |
TCR and B2M knockout |
NCT03166878 |
| Tumor of the central nervous system | NF1 | — | Fix NF1 mutation allele | NCT03332030 |
| Multiple myeloma Melanoma Synovial sarcoma Myxoid/round cell liposarcoma |
TCR PD-1 |
Phase I | TCR and PD-1 knockout | NCT03399448 |